TR201820824T4 - IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler. - Google Patents

IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler. Download PDF

Info

Publication number
TR201820824T4
TR201820824T4 TR2018/20824T TR201820824T TR201820824T4 TR 201820824 T4 TR201820824 T4 TR 201820824T4 TR 2018/20824 T TR2018/20824 T TR 2018/20824T TR 201820824 T TR201820824 T TR 201820824T TR 201820824 T4 TR201820824 T4 TR 201820824T4
Authority
TR
Turkey
Prior art keywords
ifn
modulators
amide
alpha
substituted heterocyclic
Prior art date
Application number
TR2018/20824T
Other languages
English (en)
Inventor
M Moslin Ryan
S Weinstein David
T Wrobleski Stephen
S Tokarski John
Kumar Amit
G Batt Douglas
Lin Shuqun
Liu Chunjian
H Spergel Steven
Zhang Yanlei
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876960&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201820824(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of TR201820824T4 publication Critical patent/TR201820824T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Aşağıdaki formüle (I) veya burada R1, R2, R3, R4 ve R5 olarak tanımlanan, bir stereoizomer veya bunun farmasötik olarak kabul edilebilir tuzuna sahip olan bileşikler, sinyal iletme inhibisyonuna neden olmak üzere Tyk-2 üzerinde hareket ettirilerek, IL-12, IL-23 ve/veya IFNa modülasyonunda faydalıdır.
TR2018/20824T 2012-11-08 2013-11-07 IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler. TR201820824T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261723840P 2012-11-08 2012-11-08

Publications (1)

Publication Number Publication Date
TR201820824T4 true TR201820824T4 (tr) 2019-01-21

Family

ID=49876960

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/20824T TR201820824T4 (tr) 2012-11-08 2013-11-07 IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler.

Country Status (38)

Country Link
US (6) USRE47929E1 (tr)
EP (3) EP3495358B8 (tr)
JP (3) JP6407159B2 (tr)
KR (1) KR102195194B1 (tr)
CN (1) CN104884454B (tr)
AR (1) AR094452A1 (tr)
AU (4) AU2013341186B2 (tr)
BR (1) BR112015010102B1 (tr)
CA (1) CA2890981C (tr)
CL (1) CL2015001231A1 (tr)
CY (1) CY1121188T1 (tr)
DK (2) DK2922846T3 (tr)
EA (1) EA028814B1 (tr)
ES (2) ES2702148T3 (tr)
FI (1) FIC20230028I1 (tr)
FR (1) FR23C1030I1 (tr)
HK (1) HK1215255A1 (tr)
HR (2) HRP20220766T1 (tr)
HU (3) HUE059409T2 (tr)
IL (1) IL238610A0 (tr)
LT (3) LT3495358T (tr)
MA (1) MA38072A1 (tr)
MX (2) MX2015005731A (tr)
MY (2) MY175448A (tr)
NL (1) NL301238I2 (tr)
NZ (1) NZ708859A (tr)
PE (1) PE20150944A1 (tr)
PH (1) PH12015501004A1 (tr)
PL (2) PL3495358T3 (tr)
PT (2) PT2922846T (tr)
RS (2) RS63328B1 (tr)
SG (3) SG10201706985UA (tr)
SI (2) SI3495358T1 (tr)
TR (1) TR201820824T4 (tr)
TW (1) TWI605041B (tr)
UY (1) UY35126A (tr)
WO (1) WO2014074661A1 (tr)
ZA (1) ZA201504052B (tr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540333B2 (en) 2012-11-08 2017-01-10 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNα
KR102195194B1 (ko) * 2012-11-08 2020-12-24 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 아미드-치환된 헤테로시클릭 화합물
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
WO2015123453A1 (en) * 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
RU2020124922A (ru) 2015-11-26 2020-08-10 Новартис Аг Новые производные диаминопиридина
TWI825663B (zh) 2016-10-14 2023-12-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
JP7082120B2 (ja) 2016-10-21 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
US10294256B2 (en) 2016-12-13 2019-05-21 Bristol-Myers Squibb Company Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
EP4338802A2 (en) 2017-03-08 2024-03-20 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
BR112019020169A2 (pt) * 2017-03-30 2020-04-22 Bristol-Myers Squibb Company processo para a preparação de 6-(ciclopropanoamido)-4-((2-metóxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3-carboxamida
JP7258903B2 (ja) * 2017-11-21 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー スルホンピリジンアルキルアミド置換ヘテロアリール化合物
WO2019178079A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
US11597721B2 (en) 2018-03-22 2023-03-07 Bristol-Myers Squibb Company Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses
EP3810599A1 (en) * 2018-05-31 2021-04-28 Bristol-Myers Squibb Company Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
KR20210095634A (ko) * 2018-10-22 2021-08-02 에스커 테라퓨틱스, 인크. Tyk2 억제제 및 이의 용도
KR20210086674A (ko) * 2018-10-30 2021-07-08 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
US11053241B2 (en) 2018-11-30 2021-07-06 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3914357A4 (en) 2019-01-23 2022-10-12 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND THEIR USES
KR20210119426A (ko) * 2019-01-28 2021-10-05 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
KR20210121140A (ko) * 2019-01-30 2021-10-07 브리스톨-마이어스 스큅 컴퍼니 아미드-이치환된 피리딘 또는 피리다진 화합물
IL287665A (en) * 2019-04-30 2022-07-01 Celgene Corp Combined treatments including apremilaste and tyk2 inhibitors
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
CN114174284A (zh) * 2019-06-12 2022-03-11 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-***-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的结晶盐形式
EP3999499A1 (en) * 2019-07-16 2022-05-25 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
EP4007757A4 (en) * 2019-08-01 2023-07-19 Integral Biosciences Pvt. Ltd. HETEROCYCLIC COMPOUND AS KINASE INHIBITORS AND USES THEREOF
KR20220105631A (ko) 2019-09-13 2022-07-27 님버스 새턴 인코포레이티드 Hpk1 길항제 및 이의 용도
US20230255964A1 (en) 2019-09-18 2023-08-17 Bristol-Myers Squibb Company Extended release dosage forms for tyk2 inhibitors
CN114787152A (zh) * 2019-12-27 2022-07-22 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
US20230159520A1 (en) * 2020-02-26 2023-05-25 Beigene, Ltd. Tyk-2 inhibitor
CA3170773A1 (en) 2020-03-11 2021-09-16 Xiangyang Chen Heterocyclic compounds for inhibiting tyk2 activities
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
JP2023523438A (ja) * 2020-04-28 2023-06-05 ブリストル－マイヤーズ スクイブ カンパニー 置換ヘテロ環式化合物
CN113563309A (zh) * 2020-04-28 2021-10-29 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113773262A (zh) * 2020-06-09 2021-12-10 江苏先声药业有限公司 哒嗪类化合物
CA3186000A1 (en) * 2020-07-24 2022-01-27 Shanghai Hansoh Biomedical Co., Ltd. Crystal form of pyridazine derivative free base, and preparation method therefor and use thereof
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
EP4213813A1 (en) 2020-09-18 2023-07-26 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
WO2022083649A1 (zh) * 2020-10-20 2022-04-28 杭州领业医药科技有限公司 哒嗪衍生物的晶型
WO2022100710A1 (en) * 2020-11-12 2022-05-19 Cullgen (Shanghai) , Inc. Tyrosine kinase 2 (tyk2) degradation compounds and methods of use
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN116547276A (zh) * 2020-12-08 2023-08-04 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
AU2022214313A1 (en) 2021-01-29 2023-08-17 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
AU2022216810A1 (en) 2021-02-02 2023-08-24 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022167445A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
CN117295737A (zh) 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022193499A1 (en) * 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP2024514090A (ja) 2021-03-29 2024-03-28 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態
CN115141149A (zh) * 2021-03-30 2022-10-04 浙江文达医药科技有限公司 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
CN115197196A (zh) * 2021-04-06 2022-10-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
CN117136058A (zh) 2021-05-04 2023-11-28 上海喆邺生物科技有限公司 一类含氮杂环吡啶类化合物
EP4337649A1 (en) * 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
TW202311247A (zh) * 2021-05-14 2023-03-16 美商必治妥美雅史谷比公司 經取代之雜環化合物
KR20240007242A (ko) * 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
EP4337650A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
KR20240024906A (ko) * 2021-06-22 2024-02-26 메드샤인 디스커버리 아이엔씨. 설폭시민 화합물 및 이의 용도
WO2023284869A1 (zh) * 2021-07-15 2023-01-19 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
WO2023023322A1 (en) * 2021-08-20 2023-02-23 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
TW202313035A (zh) * 2021-08-21 2023-04-01 美商傳達治療有限公司 Ｊａｋ２抑制劑及其使用方法
CA3232812A1 (en) 2021-09-23 2023-03-30 Ian MacQuarie CATLETT Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023055901A2 (en) 2021-09-30 2023-04-06 Bristol-Myers Squibb Company Methods for determining responsiveness to tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023076515A1 (en) 2021-10-28 2023-05-04 Bristol-Myers Squibb Company Topical formulations of deucravacitinib
WO2023102085A1 (en) 2021-12-01 2023-06-08 Teva Czech Industries S.R.O. Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
TW202339749A (zh) * 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Ｔｙｋ２抑制劑及其組合物和方法
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
EP4206196A1 (en) 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
WO2023231997A1 (zh) * 2022-05-31 2023-12-07 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
CN116284040A (zh) * 2023-01-05 2023-06-23 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其医药用途
CN116162093B (zh) * 2023-04-25 2023-06-23 中南大学湘雅医院 一种tyk2抑制剂化合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017898T2 (de) 1999-06-09 2006-01-12 Yamanouchi Pharmaceutical Co., Ltd. Neuartige heterocyclische carboxamidderivate
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
WO2000076980A1 (fr) 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques azotes ou leurs sels
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
EA011686B1 (ru) 2002-07-15 2009-04-28 Уайт Способ модуляции развития и функций т-клеток-хелперов
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
JP2013522267A (ja) 2010-03-17 2013-06-13 エフ．ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
WO2012035039A1 (en) 2010-09-15 2012-03-22 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
JP2013542966A (ja) 2010-11-19 2013-11-28 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロピリジンならびにｔｙｋ２阻害剤としてのピラゾロピリジン及びそれらの使用
US9145414B2 (en) * 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
MX352928B (es) * 2012-01-10 2017-12-13 Hoffmann La Roche Compuestos de piridazina-amida.
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
CA2883534A1 (en) * 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibitors of syk
US9540333B2 (en) 2012-11-08 2017-01-10 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNα
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
KR102195194B1 (ko) * 2012-11-08 2020-12-24 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 아미드-치환된 헤테로시클릭 화합물
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
BR112019020169A2 (pt) * 2017-03-30 2020-04-22 Bristol-Myers Squibb Company processo para a preparação de 6-(ciclopropanoamido)-4-((2-metóxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3-carboxamida

Also Published As

Publication number Publication date
US20170022192A1 (en) 2017-01-26
PE20150944A1 (es) 2015-06-20
AU2013341186B2 (en) 2017-03-30
US10526321B2 (en) 2020-01-07
IL238610A0 (en) 2015-06-30
CA2890981A1 (en) 2014-05-15
MA38072A1 (fr) 2016-07-29
AU2017201076A1 (en) 2017-03-09
HUE041750T2 (hu) 2019-05-28
AR094452A1 (es) 2015-08-05
US9505748B2 (en) 2016-11-29
SG11201503399XA (en) 2015-05-28
MY175448A (en) 2020-06-29
AU2020203967A1 (en) 2020-07-16
HUE059409T2 (hu) 2022-11-28
HRP20220766T1 (hr) 2022-09-16
LT2922846T (lt) 2018-12-10
JP6407159B2 (ja) 2018-10-17
PH12015501004B1 (en) 2015-07-27
US20220356180A1 (en) 2022-11-10
ZA201504052B (en) 2017-11-29
US20180265504A1 (en) 2018-09-20
DK2922846T3 (en) 2019-01-21
BR112015010102B1 (pt) 2022-02-08
EA201590917A1 (ru) 2015-09-30
UY35126A (es) 2014-05-30
AU2020203967B2 (en) 2020-10-22
EP4071144A1 (en) 2022-10-12
TW201422593A (zh) 2014-06-16
DK3495358T3 (da) 2022-05-23
LT3495358T (lt) 2022-05-25
CN104884454B (zh) 2017-11-28
HUS2300025I1 (hu) 2023-08-28
EP2922846A1 (en) 2015-09-30
RS63328B1 (sr) 2022-07-29
TWI605041B (zh) 2017-11-11
JP6585231B2 (ja) 2019-10-02
EP2922846B1 (en) 2018-10-03
KR20150081339A (ko) 2015-07-13
LTPA2023523I1 (tr) 2023-09-11
PL3495358T3 (pl) 2022-06-27
AU2018267545A1 (en) 2018-12-13
US20200071315A1 (en) 2020-03-05
EP3495358A1 (en) 2019-06-12
ES2702148T3 (es) 2019-02-27
KR102195194B1 (ko) 2020-12-24
USRE47929E1 (en) 2020-04-07
FR23C1030I1 (fr) 2023-10-13
BR112015010102A2 (pt) 2017-07-11
MY194668A (en) 2022-12-12
MX2015005731A (es) 2015-09-16
SI3495358T1 (sl) 2022-06-30
PH12015501004A1 (en) 2015-07-27
SG10201706985UA (en) 2017-10-30
PL2922846T3 (pl) 2019-03-29
PT2922846T (pt) 2018-12-19
JP2020002157A (ja) 2020-01-09
NL301238I2 (nl) 2023-10-04
CA2890981C (en) 2022-07-05
HRP20181937T1 (hr) 2019-01-25
CL2015001231A1 (es) 2015-08-28
JP2016506369A (ja) 2016-03-03
US10000480B2 (en) 2018-06-19
AU2013341186A1 (en) 2015-07-02
SI2922846T1 (sl) 2019-04-30
WO2014074661A1 (en) 2014-05-15
SG10201706897TA (en) 2017-09-28
AU2018267545B2 (en) 2020-04-02
EP3495358B8 (en) 2022-06-08
EA028814B1 (ru) 2018-01-31
NZ708859A (en) 2018-11-30
RS58187B1 (sr) 2019-03-29
FIC20230028I1 (fi) 2023-08-28
AU2017201076B2 (en) 2018-11-15
PT3495358T (pt) 2022-06-02
JP2018154636A (ja) 2018-10-04
CN104884454A (zh) 2015-09-02
US20150299183A1 (en) 2015-10-22
US11021475B2 (en) 2021-06-01
MX2020003156A (es) 2020-07-29
HK1215255A1 (zh) 2016-08-19
CY1121188T1 (el) 2020-05-29
EP3495358B1 (en) 2022-04-27
ES2914793T3 (es) 2022-06-16

Similar Documents

Publication Publication Date Title
TR201820824T4 (tr) IL-12, IL-23 ve/veya IFN-alfa'nın modülatörleri olarak faydalı amid ile sübstitüe edilmiş heterosiklik bileşikler.
PH12016500779A1 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
EA202191142A1 (ru) Амидзамещенные гетероциклические соединения
PH12015501005A1 (en) Heteroaryl substituted pyridil compounds useful as kinase modulators
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
EA201590913A1 (ru) АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
EA201590911A1 (ru) АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
IN2014DN09068A (tr)
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
EA201590748A1 (ru) Противовирусные соединения против rsv
ATE459622T1 (de) Tropanverbindungen
EA201390633A1 (ru) Новые вещества для повторно перерабатываемых эпоксидных смол
MY169043A (en) New dihydroquinoline-2-one derivatives
RS54730B1 (sr) Inhibitori beta sekretaze
EA201201170A1 (ru) Гетариламинонафтиридины
RS54488B1 (en) NALOXOL-POLYETHYLENE GLYCOL CRYSTAL CONJUGATE
JO3318B1 (ar) مثبطات bace
GB201305247D0 (en) Amide Compounds
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
PH12015501146A1 (en) Hydantoin derivative
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
MX2015011005A (es) Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.
EA201201674A1 (ru) Способы разделения замещенных по атому азота производных (s)-5-алкокси-2-аминотетралина
TH161045B (th) สารประกอบเฮเทอโรไซคลิกที่ถูกแทนที่ด้วยเอมีดที่มีประโยชน์เป็นโมดูเลเตอร์ ของการตอบสนอง il-12, il-23 และ/หรือ ifn?
UA123797U (uk) Похідні бензиліденаніліну як інгібітори тирозинази